Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AstraZeneca Pharma India's enterprise value is ₹201,113 Mil.
AstraZeneca Pharma India's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2,853 Mil. Therefore, AstraZeneca Pharma India's EV-to-EBITDA for today is 70.50.
The historical rank and industry rank for AstraZeneca Pharma India's EV-to-EBITDA or its related term are showing as below:
NSE:ASTRAZEN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 30.59 Med: 64.08 Max: 143.47
Current: 70.5
During the past 13 years, the highest EV-to-EBITDA of AstraZeneca Pharma India was 143.47. The lowest was 30.59. And the median was 64.08.
NSE:ASTRAZEN's EV-to-EBITDA is ranked worse than 93.29% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.91
vs NSE:ASTRAZEN: 70.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
AstraZeneca Pharma India (NSE:ASTRAZEN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AstraZeneca Pharma India's PE Ratio (TTM) for today is calculated as:
AstraZeneca Pharma India's share price for today is ₹8185.00.
AstraZeneca Pharma India's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹75.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's EV-to-EBITDA falls into.
AstraZeneca Pharma India's current Enterprise Value is ₹201,113 Mil.
AstraZeneca Pharma India's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,853 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a EV-to-EBITDA of 70.50 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AstraZeneca Pharma India. This is 10% above median its historical median of 64.08. Over the past decade, AstraZeneca Pharma India's EV-to-EBITDA has ranged from 30.59 to 143.47. According to the industry distribution chart, AstraZeneca Pharma India ranks #695 out of 745 companies in the Drug Manufacturers industry, placing it in the top 93.3%.
Is AstraZeneca Pharma India's EV-to-EBITDA too high?
AstraZeneca Pharma India's current EV-to-EBITDA of 70.50 is 10% above median its 10-year median of 64.08. Over the past 10 years, this metric has ranged from a low of 30.59 to a high of 143.47. The Drug Manufacturers industry median EV-to-EBITDA is 12.91. AstraZeneca Pharma India's value of 70.50 is 446.1% above this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #695 out of 745 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AstraZeneca Pharma India has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #695 out of 745 companies for EV-to-EBITDA. This places AstraZeneca Pharma India in the lower half of its industry. The industry median EV-to-EBITDA is 12.91. AstraZeneca Pharma India's value of 70.50 is 446.1% above this benchmark. Historically, AstraZeneca Pharma India's own EV-to-EBITDA has ranged from 30.59 to 143.47 over the past decade. While the company's 10-year median is 64.08 vs. the industry median of 12.91, AstraZeneca Pharma India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.91, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current EV-to-EBITDA of 70.50 is 446.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AstraZeneca Pharma India. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current EV-to-EBITDA is 70.50, which is 10% above median its own 10-year median of 64.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹11,046.82, compared to a current price of ₹8,185.00 — trading 25.9% below its estimated fair value. The current EV-to-EBITDA is 70.50, which is 10% above median its 10-year median of 64.08 and 446.1% above the Drug Manufacturers industry median of 12.91. AstraZeneca Pharma India's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current EV-to-EBITDA is 70.50 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,185.00 is trading 25.9% below its estimated GF Value™ of ₹11,046.82.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
EV-to-EBITDA: 70.50 (10% above median its 10-year median of 64.08)
GF Value™: ₹11,046.82 vs. price of ₹8,185.00 (25.9% below fair value)
Industry Position: 446.1% above the Drug Manufacturers median (#695 of 745)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
90GF Score
Get the complete analysis for NSE:ASTRAZEN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
